Advertisement

Neuroendocrine Changes during the Course of Neuroleptic Treatment of Schizophrenic Patients

  • Norbert Nedopil
  • Johannes Weiss-Brummer
  • Eckart Rüther

Abstract

The blockade of postsynaptic dopaminergic receptors is considered to be the most important biological factor in the action of neuroleptic drugs for the treatment of schizophrenia (Carlsson, 1978; Johnstone et al., 1978). A wide variety of indirect evidence (Crow et al., 1976; Van Kammen, 1979; Snyder, 1976; Meltzer and Stahl, 1976) and some direct evidence in postmortem brains of schizophrenic patients (Lee and Seeman, 1977) supported the dopamine hypothesis of schizophrenia, i.e., that the productive symptoms of schizophrenia are associated with a relative excess of dopaminergic activity in certain subcortical brain structures.

Keywords

Schizophrenic Patient Growth Hormone Secretion Human Growth Hormone Growth Hormone Response Neuroleptic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beumont, P. J. V., Gelder, M. G., Friesen, H. G., Harris, G. W., MacKinnon, P. C. B., Mandelbrote, B. M., and Wiles, D. H., 1974, The effects of phenothiazines on endocrine function. I. Patients with inappropriate lactation and amenorrhea, Br. J. Psychiatry 124:413.PubMedCrossRefGoogle Scholar
  2. Brown, W. A., and Laughren, T., 1981, Low serum prolactin and early relapse following neuroleptic withdrawal, Am. J. Psychiatry 138:237.PubMedGoogle Scholar
  3. Brown, W. A., van Woert, M. H., and Ambani, L. M., 1973, Effect of apomorphine on growth hormone release in humans, J. Clin. Endocrinol. Metab. 37:463.PubMedCrossRefGoogle Scholar
  4. Carlsson, A., 1978, Antipsychotic drugs, neurotransmitters and schizophrenia, Am. J. Psychiatry 135:164.Google Scholar
  5. Corsini, G. U., Onali, P., Masala, C., Cianchetti, C., Mangoni, A., and Gessa, G., 1978, Apomorphine hydrochloride induced improvement in Huntington’s chorea: Stimulation of dopamine receptor, Arch. Neurol. 35:27.PubMedCrossRefGoogle Scholar
  6. Crow, T. J., Deakin, J. F. W., Johnstone, E. C., and Longden, A., 1976, Dopamine and schizophrenia, Lancet II:563.CrossRefGoogle Scholar
  7. Davis, J. M., 1974, Dose equivalence of the antipsychotic drugs, J. Psychiatr. Res. 11:65.PubMedCrossRefGoogle Scholar
  8. De Rivera, J. L., Lal, S., Ettigi, P., Hontela, S., Muller, H. F., and Friesen, H. G., 1976, Effects of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups, Clin. Endocrinol. 5:273.CrossRefGoogle Scholar
  9. Endicott, J., Spitzer, R. L., Fleiss, J. V., and Cohen, J., 1976, The global assessment scale: A procedure for measuring overall severity of psychiatric disturbances, Arch. Gen Psychiatry 33:766.PubMedCrossRefGoogle Scholar
  10. Ettigi, P., Nair, N. P. V., Lal, S., Cervantes, P., and Guyda, H., 1976, Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy, J. Neurol. Neurosurg. Psychiatry 39:870.PubMedCrossRefGoogle Scholar
  11. Feinberg, M., and Carroll, B. J., 1979, Effects of dopamine agonists and antagonists in Tourette’s disease, Arch. Gen. Psychiatry 36:979.PubMedCrossRefGoogle Scholar
  12. Gruen, P. H., Sachar, E. J., Altman, N., Langer, G., Tabrizi, M. A., and Halpern, F. S., 1978, Relation of plasma prolactin to clinical response in schizophrenic patients, Arch. Gen. Psychiatry 35:1222.PubMedCrossRefGoogle Scholar
  13. Haase, H. J., 1978, Therapie mit Psychopharmaka und anderen seelisches Befinden beeinflussenden Medikamenten, pp. 121–136, Schattauer, Munich.Google Scholar
  14. Hays, S. E., and Rubin, R. T., 1979, Variability of prolactin response to intravenous and intramuscular haloperidol in normal adult men, Psychopharmacology 61:17.PubMedCrossRefGoogle Scholar
  15. Johnstone, E. C., Crow, T. J., Frith, C. D., Carney, M. W. P., and Price, J. S., 1978, Mechanism of the antipsychotic effect in the treatment of acute schizophrenia, Lancet I:848.CrossRefGoogle Scholar
  16. Kolakowska, T., Wiles, D. H., McNeilly, A. S., and Gelder, M. G., 1975, Correlation between plasma levels of prolactin and chlorpromazine in psychiatric patients, Psychol. Med. 5:214.PubMedCrossRefGoogle Scholar
  17. Lal, S., De la Vega, C. E., Sourkes, T. L., and Friesen, H. G., 1973, Effect of apomorphine on growth hormone, prolactin, luteinizing hormone and follicle-stimulating hormone levels in human serum, J. Clin. Endocrinol. Metab. 37:719.PubMedCrossRefGoogle Scholar
  18. Lal, S., Guyda, H., and Bikadoroff, S., 1977, Effect of methysergide and pimozide on apomorphine-induced growth hormone secretion in men, J. Clin. Endocrinol. Metab. 44:766.PubMedCrossRefGoogle Scholar
  19. Langer, G., Sachar, E. J., Halpern, F. S., Gruen, P. H., and Solomon, M., 1977, The prolactin response to neuroleptic drugs. A test of dopaminergic blockade: Neuroendocrine studies in normal men, J. Clin. Endocrinol. Metab. 45:996.PubMedCrossRefGoogle Scholar
  20. Lee, T., and Seeman, P., 1977, Dopamine receptors in normal and schizophrenic brains, Neurosci. Abstr. 3:443.Google Scholar
  21. MacLeod, R. M., 1976, Regulation of prolactin secretion, in: Frontiers in Neuroendocrinology (L. Martini and W. F. Ganong, eds.), Vol. 4, pp. 189–194, Raven Press, New York.Google Scholar
  22. Martin, J. B., 1976, Brain regulation of growth hormone secretion, in: Frontiers in Neuroendocrinology (L. Martini and W. F. Ganong, eds.), Vol. 4, pp. 129–168, Raven Press, New York.Google Scholar
  23. Meltzer, H. Y., 1979, Biochemical studies in schizophrenia, in: Disorders of the Schizophrenic Syndrome (L. Bellak, ed.), pp. 45–135, Basic Books, New York.Google Scholar
  24. Meltzer, H. Y., and Fang, V. S., 1976, The effect of neuroleptics on serum prolactin in schizophrenic patients, Arch. Gen. Psychiatry 33:279.PubMedCrossRefGoogle Scholar
  25. Meltzer, H. Y., and Stahl, S. M., 1976, The dopamine hypothesis of schizophrenia: A review, Schizophr. Bull. 2:19.PubMedGoogle Scholar
  26. Meltzer, H. Y., Fang, V. S., and Goode, D. J., 1978, The effect of neuroleptics and alpha-methyl-paratyrosine and serum prolactin levels in laboratory animals and man, Psychopharmacol. Bull. 14:5.PubMedGoogle Scholar
  27. Müller, F., Ackenheil, M., Albus, M., May, G., and Zander, K., 1981, Changes in dopamine receptor sensitivity of chronic schizophrenics after long-term neuroleptic treatment and after drug withdrawal. Third World Congress of Psychiatry (Abstract).Google Scholar
  28. Naber, D., Ackenheil, M., Laakmann, G., Fischer, H., and von Werder, K., 1980, Basal and stimulated levels of prolactin, TSH and LH in serum of chronic schizophrenic patients, long term treated with Neuroleptics. Pharmakopsychiatr. Neuro-Psychopharmakol. 13:325.Google Scholar
  29. Nair, N. P., Lal, S., Cervantes, P., Yassa, R., and Guyda, H., 1979, Effect of clozapine on apomorphine-induced growth hormone secretion and serum prolactin concentrations in schizophrenia, Neuropsychobiology 5:136.PubMedCrossRefGoogle Scholar
  30. Overall, J. E., and Gorham, D. R., 1962. The Brief Psychiatric Rating Scale, Psychol. Rep. 10:799.Google Scholar
  31. Pandey, G. N., Garver, D. L., Tamminga, C., Ericksen, S., Ali, S. I., and Davis, J. M., 1977, Postsynaptic supersensitivity in schizophrenia, Am. J. Psychiatry 134:518.PubMedGoogle Scholar
  32. Rotrosen, J., Angrist, B. M., Gershon, S., Sachar, E. J., and Halpern, F. S., 1976, Dopamine receptor alteration in schizophrenia: Neuroendocrine evidence, Psychopharmacology 51:1.PubMedCrossRefGoogle Scholar
  33. Rotrosen, J., Angrist, B. M., Gershon, S., Paquin, J., Branchey, L., Olenshansky, M., Halpern, F., and Sachar, E. J., 1979, Neuroendocrine effects of apomorphine: Characterization of response patterns and application to schizophrenia research, Br. J. Psychiatry 135:444.PubMedCrossRefGoogle Scholar
  34. Scharfetter, C. H., 1972, Das AMD-P-System, Springer, Berlin.Google Scholar
  35. Sedvall, G., Alfredsson, G., Bjerkenste, L., Eneroth, P., Fryö, B., Härnryd, C., and Wode-Helgodt, B., 1975, Biochemical correlates to antipsychotic drug action in man, in: The Impact of Biology in Modern Psychiatry (E. S. Gershon, R. E. Belmaker, S. S. Kety, and M. Rosenbaum, eds.), pp. 153–177, Plenum Press, New York.Google Scholar
  36. Simpson, G. M., and Angus, J. W., 1970, A rating scale for extrapyramidal side effects, Acta Psychiatr. Scand. 212:11.CrossRefGoogle Scholar
  37. Siris, S. G., van Kammen, D. P., and De Fraites, E. G., 1978, Serum prolactin and antipsychotic response to pimozide in schizophrenia, Psychopharmacol. Bull. 14:11.PubMedGoogle Scholar
  38. Snyder, S. H., 1972, Catecholamines in the brain as mediators of amphetamine psychosis, Prog. Neurobiol. 1:151.Google Scholar
  39. Snyder, S. H., 1976, The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor, Am. J. Psychiatry 133:197.PubMedGoogle Scholar
  40. Snyder, S. H., and Bennett, J. P., 1976, Neurotransmitter receptors in the brain: Biochemical identification, in: Biogenic Amine Receptors (L. L. Iversen, S. D. Iversen, and S. H. Snyder, eds.), pp. 153–177, Plenum Press, New York.Google Scholar
  41. Tamminga, C. A., Smith, R. C., Pandey, G., Frohman, L. A., and Davis, J. M., 1977, A neuroendocrine study of supersensitivity in tardive dyskinesia, Arch. Gen. Psychiatry 34:1199.PubMedCrossRefGoogle Scholar
  42. Van Kammen, D. P., 1979, The dopamine hypothesis of schizophrenia revisited, Psychoneuroen-docrinology 4:37.CrossRefGoogle Scholar
  43. WHO (World Health Organization), 1974, International classification of diseases, WHO, Geneva.Google Scholar
  44. Wode-Helgodt, B., Borg, S., Fryö, B., and Sedvall, G., 1978, Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine, Acta Psychiatr. Scand 58:149.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1984

Authors and Affiliations

  • Norbert Nedopil
    • 1
  • Johannes Weiss-Brummer
    • 1
  • Eckart Rüther
    • 1
  1. 1.Psychiatric Hospital of the University of MunichMunich 2Germany

Personalised recommendations